162 related articles for article (PubMed ID: 21748299)
1. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Goto Y; Sekine I; Tanioka M; Shibata T; Tanai C; Asahina H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kikkawa H; Ohki E; Tamura T
Invest New Drugs; 2012 Aug; 30(4):1548-56. PubMed ID: 21748299
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
Karp DD; Pollak MN; Cohen RB; Eisenberg PD; Haluska P; Yin D; Lipton A; Demers L; Leitzel K; Hixon ML; Terstappen LW; Garland L; Paz-Ares LG; Cardenal F; Langer CJ; Gualberto A
J Thorac Oncol; 2009 Nov; 4(11):1397-403. PubMed ID: 19745765
[TBL] [Abstract][Full Text] [Related]
4. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.
Langer CJ; Novello S; Park K; Krzakowski M; Karp DD; Mok T; Benner RJ; Scranton JR; Olszanski AJ; Jassem J
J Clin Oncol; 2014 Jul; 32(19):2059-66. PubMed ID: 24888810
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
Horinouchi H; Yamamoto N; Fujiwara Y; Sekine I; Nokihara H; Kubota K; Kanda S; Yagishita S; Wakui H; Kitazono S; Mizugaki H; Tokudome T; Tamura T
Invest New Drugs; 2015 Aug; 33(4):881-9. PubMed ID: 25924991
[TBL] [Abstract][Full Text] [Related]
8. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Doebele RC; Conkling P; Traynor AM; Otterson GA; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge DR
Ann Oncol; 2012 Aug; 23(8):2094-2102. PubMed ID: 22345119
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
[TBL] [Abstract][Full Text] [Related]
10. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Gualberto A; Hixon ML; Karp DD; Li D; Green S; Dolled-Filhart M; Paz-Ares LG; Novello S; Blakely J; Langer CJ; Pollak MN
Br J Cancer; 2011 Jan; 104(1):68-74. PubMed ID: 21102589
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
[TBL] [Abstract][Full Text] [Related]
13. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Thomas M; Sadjadian P; Kollmeier J; Lowe J; Mattson P; Trout JR; Gargano M; Patchen ML; Walsh R; Beliveau M; Marier JF; Bose N; Gorden K; Schneller F
Invest New Drugs; 2017 Jun; 35(3):345-358. PubMed ID: 28303530
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
Karp DD; Paz-Ares LG; Novello S; Haluska P; Garland L; Cardenal F; Blakely LJ; Eisenberg PD; Langer CJ; Blumenschein G; Johnson FM; Green S; Gualberto A
J Clin Oncol; 2009 May; 27(15):2516-22. PubMed ID: 19380445
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Okamoto I; Yamamoto N; Kubota K; Ohe Y; Nogami N; Murakami H; Yamaya H; Ono K; Nakagawa K
Invest New Drugs; 2012 Jun; 30(3):1132-7. PubMed ID: 21537886
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Giaccone G; Huizing M; Postmus PE; ten Bokkel Huinink WW; Koolen M; van Zandwijk N; Vermorken JB; Beijnen JH; Dalesio O; Pinedo HM
Semin Oncol; 1995 Aug; 22(4 Suppl 9):78-82. PubMed ID: 7544030
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
[TBL] [Abstract][Full Text] [Related]
20. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
